SUPPLEMENTARY MATERIAL

Figure S1. Specificity of the anti-BACE antibodies used in this study

The specificity of two anti-BACE antibodies (D10E5, N-terminus, Cell Signaling; MAB5308, C-terminus, Chemicon) was tested using brain homogenates from a SAD case, 7-days old (P7) wild type and BACE1 -/- mice (a kind gift from Bart De Strooper). Western blot analysis showed absence of BACE1 immunoreactivity (arrowhead) in samples from P7 BACE1 -/- mice.

Figure S2. Western blot analyses of APP CTFs in human brain samples

APP-FL and APP CTFs were detected by using a rabbit APP C-terminal antibody. Cell lysates from CHO cells overexpressing APP treated with the -secretase inhibitor DAPT were used as a control (a). Densitometric analysis of the ratio APP-CTF-/APP-FL from YC and ADAD (b), SAD and ADAD (c), and EC and SAD (d). Values represent the mean of al least three indendent experiments. Values are expressed as a % of controls (b, d) or SAD (c).

Figure S3. Anti-APP antibodies label dystrophic neurites of senile plaques in ADAD

Both anti-C-terminal (a1) and anti-N-terminal (a2) APP antibodies detect dystrophic neurites in a patient with the APP I716F mutation. In addition to APP, tau (a3) and ubiquitin (a4) antibodies label the neuritic component of amyloid plaques. Bar 50 μm

80

7. References

1. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011 Jan;3(1):1– 13.

2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353–356.

3. Lleó A, Saura CA. Y-secretase substrates and their implications for drug development in Alzheimer’s disease. Curr Top Med Chem. 2011;11(12):1513–1527.

4. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002 Sep;59(9):1381–1389. 5. Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic

Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415–6420.

6. Holsinger RMD, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol. 2002 Jun;51(6):783–786. 7. Li R, Lindholm K, Yang L, et al. Amyloid beta peptide load is correlated with increased beta-

secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3632–3637.

8. Yang L-B, Lindholm K, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003 Jan;9(1):3–4.

9. Hata S, Fujishige S, Araki Y, et al. Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer’s disease: evidence for γ-secretase dysfunction. Ann Neurol. 2011 Jun;69(6):1026–1031.

10. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010 Dec 24;330(6012):1774.

11. Portelius E, Andreasson U, Ringman JM, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener. 2010 Jan;5:2.

12. Portelius E, Bogdanovic N, Gustavsson MK, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease. Acta

Neuropathol. 2010 Aug;120(2):185–193.

13. Portelius E, Fortea J, Molinuevo JL, Gustavsson MK, Andreasson U, Sanchez-Valle R. The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P- associated Alzheimer’s disease. Mol Med Rep. 2012 Apr;5(4):1111–1115.

14. Russo C, Schettini G, Saido TC, et al. Presenilin-1 mutations in Alzheimer’s disease. Nature. 2000 Jun 1;405(6786):531–532.

15. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I. Familial Alzheimer disease associated with A713T mutation in APP. Neurosci Lett. 2004 Nov 11;370(2-3):241–243.

16. Guardia-Laguarta C, Pera M, Clarimón J, et al. Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J Neuropathol Exp Neurol. 2010 Jan;69(1):53–59.

17. Lladó A, Sánchez-Valle R, Rey MJ, et al. [New mutation in the PSEN1 (E120G) gene associated with early onset Alzheimer’s disease+. Neurología. 2010 Jan;25(1):13–16.

18. Lleó A, Blesa R, Queralt R, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol. 2002 Nov;59(11):1759–1763.

19. Sepulveda-Falla D, Glatzel M, Lopera F. Phenotypic profile of early-onset familial Alzheimer’s disease caused by presenilin-1 E280A mutation. J Alzheimer’s Dis. 2012 Jan;32(1):1–12. 20. Sepulveda-Falla D, Matschke J, Bernreuther C, et al. Deposition of hyperphosphorylated tau in

cerebellum of PS1 E280A Alzheimer’s disease. Brain Pathol. 2011 Jul;21(4):452–463. 21. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and

neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb cortex. 1991 Jan;1(1):103–116.

22. Fortea J, Lladó A, Clarimón J, et al. PICOGEN: five years experience with a genetic counselling program for dementia. Neurologia. 2011 Apr;26(3):143–149.

23. Fortea J, Lladó A, Bosch B, et al. Cerebrospinal fluid biomarkers in Alzheimer’s disease families with PSEN1 mutations. Neurodegener Dis. 2011 Jan;8(4):202–207.

24. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004 Feb;164(2):719– 725.

25. Zhong Z, Ewers M, Teipel S, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007 Jun;64(6):718–726. 26. Dominguez D, Tournoy J, Hartmann D, et al. Phenotypic and biochemical analyses of BACE1-

and BACE2-deficient mice. J Biol Chem. 2005 Sep 2;280(35):30797–30806.

27. Holsinger RMD, McLean CA, Collins SJ, Masters CL, Evin G. Increased B-secretase activiy in cerebrospinal fluid of Alzheimer’s disease subjects. Ann Neurol. 2004 Jun;55(6):898. 28. Lewczuk P, Kamrowski-Kruck H, Peters O, et al. Soluble amyloid precursor proteins in the

cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry. 2010 Feb;15(2):138–145.

29. Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008 Aug;65(8):1102–1107.

30. Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7552–7556.

82

31. Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D. Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol. 1991 Feb;138(2):373–384.

32. Perry G, Lipphardt S, Mulvihill P, et al. Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet. 1988 Sep 24;2(8613):746.

33. Shepherd C, McCann H, Halliday GM. Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol. 2009 Jul;118(1):37–52.

34. Balasa M, Vidal-Piñeiro D, Lladó A, et al. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer’s disease patients but no differences in neuronal injury biomarkers. J Alzheimers Dis. 2012 Jan;30(3):605–616. 35. Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. 2010

May;9(5):387–398.

36. Cai Y, Xiong K, Zhang X-M, et al. β-Secretase-1 elevation in aged monkey and Alzheimer’s disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation. Eur J Neurosci. 2010

Oct;32(7):1223–1238.

37. Giliberto L, Borghi R, Piccini A, et al. Mutant presenilin 1 increases the expression and activity of BACE1. J Biol Chem. 2009 Apr 3;284(14):9027–9038.

38. Aso E, Lomoio S, López-González I, et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer’s disease. Brain Pathol. 2012 Sep;22(5):636–653.

39. Rosén C, Andreasson U, Mattsson N, et al. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer’s disease. Neuromolecular Med. 2012 Mar;14(1):65–73.

40. Cirrito JR, May PC, O’Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003 Oct 1;23(26):8844–8853.

41. Yamada K, Cirrito JR, Stewart FR, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011 Sep 14;31(37):13110–13117.

42. Preece P, Virley DJ, Costandi M, et al. Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer’s disease. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):155–158.

43. Coma M, Guix FX, Ill-Raga G, et al. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol Aging. 2008 Jul;29(7):969–980.

44. Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal anti-inflammatory drugs repress beta- secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):443–448.

45. Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis. 2002 Aug;10(3):279–288.

46. Berezovska O, Lleo A, Herl LD, et al. Familial Alzheimer’s disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci. 2005 Mar 16;25(11):3009–3017.

47. Chau D-M, Crump CJ, Villa JC, Scheinberg DA, Li Y-M. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. J Biol Chem. 2012 May

18;287(21):17288–17296.

48. Chávez-Gutiérrez L, Bammens L, Benilova I, et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012 May 16;31(10):2261–2274.

49. Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 2011

Jun;25(6):1934–1942.

50. Jiang Y, Mullaney KA, Peterhoff CM, et al. Alzheimer’s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1630–1635.

51. Kim H-S, Kim E-M, Lee J-P, et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J. 2003 Oct;17(13):1951–1953.

52. McPhie DL, Lee RK, Eckman CB, et al. Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. J Biol Chem. 1997 Oct 3;272(40):24743– 24746.

53. Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci. 1996 Nov 1;16(21):6732–6741.

54. Bittner T, Fuhrmann M, Burgold S, et al. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci. 2009 Aug

19;29(33):10405–10409.

55. Mitani Y, Yarimizu J, Saita K, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012 Feb 8;32(6):2037–2050.

56. Saura CA, Chen G, Malkani S, et al. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005 Jul 20;25(29):6755–6764. 57. Ghiso J, Tagliavini F, Timmers WF, Frangione B. Alzheimer’s disease amyloid precursor protein

is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization. Biochem Biophys Res Commun. 1989 Aug 30;163(1):430–437.

58. Ishii T, Kametani F, Haga S, Sato M. The immunohistochemical demonstration of

subsequences of the precursor of the amyloid A4 protein in senile plaques in Alzheimer’s disease. Neuropathol Appl Neurobiol. 1989 Jan;15(2):135–147.

59. Nixon RA, Yang D-S. Autophagy failure in Alzheimer’s disease--locating the primary defect. Neurobiol Dis. 2011 Jul;43(1):38–45.

84

60. Lee J-H, Yu WH, Kumar A, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010 Jun 25;141(7):1146–1158.